All treatments
Treatment
Capecitabine Accord 500 mg film-coated tablets clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carcinoma. A non-comparative randomized phase II study
This study looks at treating bile duct cancer after surgery. Patients will receive either standard chemotherapy (capecitabine) or a combination of chemotherapy and a newer immune-boosting drug (durvalumab, also known as Imfinzi). The main goal is to see if the new combination helps people stay cancer-free for longer.
For: Biliary tract carcinomaFrance - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
This study looks at new drug combinations for advanced breast cancer that has spread. It focuses on a type of breast cancer called 'HER2-low'. Doctors want to see if these combinations are safe, how they work in the body, and if they can help shrink tumours.
For: Metastatic Breast CancerBelgium